In order to overcome the challenges currently facing cell and gene therapies (C>), the next generation of manufacturers must prepare to serve small and large patient populations across a wide range of care settings to harmonize clinical workflows, reduce HCP burden and deliver therapies at a fraction of the current cost. This cannot be achieved by incrementally tweaking the existing model. Rather, it requires leapfrogging the current C> 1.0 “proof-of-concept” to deliver fundamentally new capabilities. To deliver on the promise of C> 2.0, a new approach is required, one that considers the needs more holistically across the end-to-end patient journey.
In this webinar, you’ll learn about:
- Accelerating diagnosis to minimize the burden of disease
- Enhancing patient outcomes to de-risk C> treatments
- Reinforcing long-term impact to realize value creation
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.